Patients who develop cytokine release syndrome after chimeric antigen receptor T-cell therapy for autoimmune disease ...
Sequencing and re-expressing B cell receptors from lymphoma tissue of rheumatoid arthritis patients reveals polyreactive and ...
A network meta-analysis of 15 randomized trials ranks telitacicept highest for SRI-4 response in lupus but links it to more ...
This is the second of multiple studies planned to evaluate MRT-6160 (DDY391) across immune-mediated diseases; Monte Rosa eligible for additional Phase 2 study initiation milestone ...
InvestorsHub on MSN
Why is Artiva Biotherapeutics discontinuing AlloNK development and cutting 94% of its workforce?
Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) announced on October 27, 2026, that it will discontinue development of its AlloNK ...
Artiva Biotherapeutics Inc. ARTV announced it will halt further clinical development of its lead cell therapy candidate, ...
Artiva Biotherapeutics, which had been evaluating cell therapy AlloNK for the treatment of rheumatoid arthritis and other ...
Monte Rosa Therapeutics announced that its partner Novartis has started a second Phase 2 clinical study of MRT-6160 (DDY391), ...
Two late-stage clinical failures of high-value projects have not changed CEO Vas Narasimhan’s projection for Novartis over ...
The case study demonstrates a durable complete response in a heavily pretreated DLBCL patient after a single administration ...
Durable Complete Response Achieved with Single Administration of Iopofosine I 131 Provides Additional Clinical Support for the Differentiated ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results